Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas

被引:17
作者
Mikami, S
Ohashi, K
Katsube, K
Nemoto, T
Nakajima, M
Okada, Y
机构
[1] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Div Diagnost Pathol, Tokyo 1608582, Japan
[3] Novartis Pharma KK, Tsukuba Res Inst, Discovery Res, Ibaraki, Japan
[4] Tokyo Metropolitan Komagome Hosp, Div Pathol, Tokyo, Japan
[5] Tokyo Med & Dent Univ, Grad Sch, Dept Mol Pathol, Tokyo, Japan
[6] Univ Tokyo, Dept Human Pathol, Grad Sch Med, Tokyo, Japan
关键词
angiogenesis; bFGF; esophageal cancer; heparanase; VEGF;
D O I
10.1111/j.1440-1827.2004.01664.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Heparan sulfate (HS), which is degraded by heparanase, plays an important role in cell adhesion, insolubility of the extracellular matrix (ECM) and as a reservoir for various growth factors such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). In the present study, we examined the immunohistochemical expression of heparanase, bFGF and VEGF, and evaluated the correlation between their expression and microvessel density (MVD) in human esophageal carcinomas. Heparanase, bFGF and VEGF were immunolocalized predominantly to the carcinoma cells, but they were also localized to the endothelial cells of microvessels near the carcinoma cell nests. In carcinomas with invasion of the muscular layer or adventitia, heparanase staining was stronger at the invasive areas of carcinomas than the intraepithelial spread. Expression of heparanase and bFGF and the degree of MVD were associated with tumor invasion, lymph node metastasis and pathological stages. Cases with positive staining for heparanase, bFGF or VEGF tended to have a higher MVD than those without staining, and carcinomas with concomitant expression of heparanase, bFGF and VEGF showed the highest MVD. The level of heparanase mRNA expression was directly correlated with the MVD. In addition, heparanase-positive cases had a higher positive ratio of bFGF and VEGF compared with the heparanase-negative cases. These data suggest the possibility that heparanase may contribute to not only cancer cell invasion but also angiogenesis probably through degradation of HS in the ECM and release of bFGF and VEGF from the HS-containing ECM.
引用
收藏
页码:556 / 563
页数:8
相关论文
共 27 条
[11]   Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis [J].
Hulett, MD ;
Freeman, C ;
Hamdorf, BJ ;
Baker, RT ;
Harris, MJ ;
Parish, CR .
NATURE MEDICINE, 1999, 5 (07) :803-809
[12]   Quantitative analysis of heparanase gene expression in esophageal squamous cell carcinoma [J].
Ikeguchi, M ;
Fukuda, K ;
Yamaguchi, K ;
Kondo, A ;
Tsujitani, S ;
Kaibara, N .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) :297-304
[13]  
Inoue H, 2001, ONCOL REP, V8, P539
[14]   Cloning and characterization of the human heparanase-1 (HPR1) gene promoter -: Role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity [J].
Jiang, P ;
Kumar, A ;
Parrillo, JE ;
Dempsey, LA ;
Platt, JL ;
Prinz, RA ;
Xu, XL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (11) :8989-8998
[15]   Trans-activation of heparanase promoter by ETS transcription factors [J].
Lu, WC ;
Liu, YN ;
Kang, BB ;
Chen, JH .
ONCOGENE, 2003, 22 (06) :919-923
[16]   Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas [J].
Mikami, S ;
Ohashi, K ;
Usui, Y ;
Nemoto, T ;
Katsube, K ;
Yanagishita, M ;
Nakajima, M ;
Nakamura, K ;
Koike, M .
JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (10) :1062-1073
[17]   HEPARAN-SULFATE DEGRADATION - RELATION TO TUMOR INVASIVE AND METASTATIC PROPERTIES OF MOUSE B-16 MELANOMA SUBLINES [J].
NAKAJIMA, M ;
IRIMURA, T ;
DIFERRANTE, D ;
DIFERRANTE, N ;
NICOLSON, GL .
SCIENCE, 1983, 220 (4597) :611-613
[18]   ACTIVATED LYMPHOCYTES-T PRODUCE A MATRIX-DEGRADING HEPARAN-SULFATE ENDOGLYCOSIDASE [J].
NAPARSTEK, Y ;
COHEN, IR ;
FUKS, Z ;
VLODAVSKY, I .
NATURE, 1984, 310 (5974) :241-244
[19]  
PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
[20]  
Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO